Syndax Pharmaceuticals Inc (SNDX NASDAQ) stock market data APIs
$16.8419
0.25(1.5%)
as of November 19, 2025
Try our APIs with
free plan!
Syndax Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Prev. Close
16.8419
Open
17.0902
High
17.4231
Low
16.7388
52 wk Range
8.58-18
Market Cap
1 452 M
Shares Outstanding
86 915 K
Revenue
111 M
EPS
-0.7
Beta
0.516
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Syndax Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Syndax Pharmaceuticals Inc data using free add-ons & libraries
Get Syndax Pharmaceuticals Inc Fundamental Data
Syndax Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 111 M
- EBITDA: -306 897 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-03
- EPS/Forecast: -0.73
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Syndax Pharmaceuticals Inc News
New
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating
With significant upside potential, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts.JPMorgan Reduces PT on Syndax...
Syndax Pharmaceuticals Stock Earns RS Rating Upgrade
A Relative Strength Rating upgrade for Syndax Pharmaceuticals shows improving technical performance. Will it continue? Continue Reading View Comments
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
Puma Biotechnology PBYI reported third-quarter 2025 adjusted earnings of 21 cents per share, which beat the Zacks Consensus Estimate of 9 cents. In the year-ago quarter, the company had reported adjus...
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia Pharmaceuticals ACAD reported third-quarter 2025 earnings of 26 cents per share (excluding a one-time tax benefit), which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
